Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer
Phase II Clinical Trial of Intravenous Paclitaxel and Carboplatin Plus Intraperitoneal Paclitaxel as an Adjuvant Chemotherapy in Patients With Optimally Debulked Advanced Epithelial Ovarian Carcinoma
Most patients with advanced ovarian cancer suffered recurrences. Therefore, adjuvant therapy is recommended for all patients with advanced ovarian cancer.
Traditionally, intravenous paclitaxel + carboplatin has been the standard adjuvant therapy.
Recently, intraperitoneal combination chemotherapy has been reported to be effective in ovarian cancer.
We attempted to evaluate the efficacy and feasibility of standard intravenous paclitaxel + carboplatin plus intraperitoneal paclitaxel chemotherapy.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Epithelial ovarian cancer is the leading cause of death from gynecologic malignancies worldwide. The recommended treatment includes primary surgery for diagnosis, staging, and cytoreduction, followed by chemotherapy. Epithelial ovarian cancer is more sensitive to cytotoxic drugs than other solid tumors, most patients with advanced ovarian cancer are recommended treatment with postoperative adjuvant chemotherapy. The recommended initial chemotherapy is generally platinum and taxane combination given by intravenous infusion every 3 weeks for 6 courses. This treatment resulted in complete remission in about 50% of ovarian cancer patients and pathologic complete response in 25~30% of patients.
However most patients with advanced ovarian cancer suffered recurrences after primary treatment, median progression free survival is 15.5-22months, and median overall survival is about 31-44months.
As residual ovarian cancer after surgery and initial recurrences are primarily confined to the abdomen, intraperitoneal administration of chemotherapy was proposed several decades ago. In 2006, Armstrong, et al., reported improvement of overall survival in ovarian cancer patient with optimal surgical debulking followed intraperitoneal paclitaxel + cisplatin chemotherapy. The National Cancer Institute (NCI) of the United States recommended to consider intraperitoneal chemotherapy in optimally debulking patients.
In Korea, however, there are few studies about postoperative adjuvant intraperitoneal chemotherapy in optimally debulked (residual mass <1cm) advanced ovarian cancer patients.
Therefore the investigators tend to evaluate the efficacy and feasibility of postoperative adjuvant intraperitoneal chemotherapy. (standard intravenous paclitaxel+carboplatin plus intraperitoneal paclitaxel chemotherapy)
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Seoul, Republica da Coréia, 139-706
- Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria:
- Age >=20 and <=75
- Histologically confirmed epithelial ovarian cancer, primary peritoneal carcinoma, tubal cancer
- Stage 3 or 4
- WBC >= 3500/mm3, ANC >= 1500/mm3, platelet >= 100000/mm3, hemoglobin >= 10 g/dl
- Serum creatinine <= upper normal limit * 1.25
- Total bilirubin <= 1.5mg/mm3, ALT/AST <= upper normal limit * 3, ALP <= upper normal limit * 3
- Adequate compliance and geographical closeness which make adequate follow-up possible
- GOG performance status 0-2
- Anticipated survival >= 3 months
- Who agreed to participate in this study and signed on informed consent form
Exclusion criteria:
- History of chemotherapy or radiotherapy on abdomen/pelvis area
- Pleural/pericardial effusion, ascites causing respiratory difficulties >= NCI-CTCAE grade 2
- History of other cancers within 5 years
- History of unapproved therapy within 30 days before enrollment
- Other serious diseases which could threat the safety of participants or impair the ability of participants to complete the participation.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: IP Chemotherapy
Patients with optimally debulked advanced (stage 3 or 4) epithelial ovarian cancer; IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5)
AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
|
IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5)
AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
2 year progression-free survival rate.
Prazo: 2 Year after initial surgery
|
The time from randomization to the time of disease progression as determined by the investigator or death from any cause. Progression is diagnosed by imaging or serial tumor marker elevation. |
2 Year after initial surgery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Median overall survival
Prazo: From entry into the study to 5 year after treatment or until half of participants are dead
|
Median observed length of life from entry into the study to death; or for living patients, the date of last contact regardless of whether or not this contact is on a subsequent protocol
|
From entry into the study to 5 year after treatment or until half of participants are dead
|
|
5 year progression-free survival rate
Prazo: 5 year after initial surgery
|
The time from randomization to the time of disease progression as determined by the investigator (by clinical, radiological or pathological means) or death from any cause
|
5 year after initial surgery
|
|
5 year overall survival rate
Prazo: 5 year after initial surgery
|
Observed length of life from entry into the study to death; or for living patients, the date of last contact regardless of whether or not this contact is on a subsequent protocol.
|
5 year after initial surgery
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: SANG YOUNG RYU, M.D., Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias Genitais Femininas
- Doenças do Sistema Endócrino
- Doenças ovarianas
- Doenças anexiais
- Distúrbios Gonadais
- Neoplasias das Glândulas Endócrinas
- Neoplasias ovarianas
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Antineoplásicos
- Moduladores de Tubulina
- Agentes Antimitóticos
- Moduladores de Mitose
- Agentes Antineoplásicos Fitogênicos
- Carboplatina
- Paclitaxel
Outros números de identificação do estudo
- KCCH GY 3001
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em IP chemotherapy
-
University Tunis El ManarConcluído
-
Johnson & Johnson Consumer Inc. (J&JCI)ConcluídoDermatite AtópicaEstados Unidos
-
Immunophotonics, Inc.RecrutamentoSarcoma de Partes Moles | Câncer de Pulmão de Células Não Pequenas | Tumor Sólido Metastático | Cancer de coloFrança, Reino Unido, Estados Unidos, Alemanha, Suíça
-
TBF Genie TissulaireAinda não está recrutando
-
TBF Genie TissulaireAinda não está recrutando
-
Vedic Lifesciences Pvt. Ltd.Concluído
-
Democritus University of ThraceConcluído
-
University Tunis El ManarDesconhecidoComplicação do TrabalhoTunísia
-
Techfields IncRescindidoPneumonia COVID-19Estados Unidos, África do Sul
-
National University of SingaporeConcluídoAuto-eficácia | Regulação da Emoção | Habilidades colaborativasCingapura